Your browser doesn't support javascript.
Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study.
Hua, Qianhui; Zhang, Hangjie; Yao, Pingping; Xu, Nani; Sun, Yisheng; Lu, Hangjing; Xu, Fang; Liao, Yuting; Yang, Juan; Mao, Haiyan; Zhang, Yanjun; Zhu, Hanping; Hu, Xiaowei; Lv, Huakun; Jiang, Jianmin.
  • Hua Q; School of Medicine, Ningbo University, Ningbo, China.
  • Zhang H; Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
  • Yao P; Department of Virus Inspection, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
  • Xu N; Department of Immunization Program, Xihu District Center for Disease Control and Prevention, Hangzhou, China.
  • Sun Y; Department of Virus Inspection, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
  • Lu H; Department of Virus Inspection, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
  • Xu F; Department of Virus Inspection, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
  • Liao Y; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China.
  • Yang J; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China.
  • Mao H; Department of Virus Inspection, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
  • Zhang Y; Department of Virus Inspection, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
  • Zhu H; Department of Virus Inspection, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
  • Hu X; Department of Immunization Program, Xihu District Center for Disease Control and Prevention, Hangzhou, China.
  • Lv H; Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
  • Jiang J; Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Front Immunol ; 13: 939311, 2022.
Article in English | MEDLINE | ID: covidwho-2022716
ABSTRACT

Background:

Owing to the coronavirus disease 2019 (COVID-19) pandemic and the emergency use of different types of COVID-19 vaccines, there is an urgent need to consider the effectiveness and persistence of different COVID-19 vaccines.

Methods:

We investigated the immunogenicity of CoronaVac and Covilo, two inactivated vaccines against COVID-19 that each contain inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The levels of neutralizing antibodies to live SARS-CoV-2 and the inhibition rates of neutralizing antibodies to pseudovirus, as well as the immunoglobulin (Ig)G and IgM responses towards the spike (S) and nucleocapsid (N) protein of SARS-CoV-2 at 180 days after two-dose vaccination were detected.

Results:

The CoronaVac and Covilo vaccines induced similar antibody responses. Regarding neutralizing antibodies to live SARS-CoV-2, 77.9% of the CoronaVac vaccine recipients and 78.3% of the Covilo vaccine recipients (aged 18-59 years) seroconverted by 28 days after the second vaccine dose. Regarding SARS-CoV-2-specific antibodies, 97.1% of the CoronaVac vaccine recipients and 95.7% of the Covilo vaccine recipients seroconverted by 28 days after the second vaccine dose. The inhibition rates of neutralizing antibody against a pseudovirus of the SARS-CoV-2 Delta variant were significantly lower compared with those against a pseudovirus of wildtype SARS-CoV-2. Associated with participant characteristics and antibody levels, persons in the older age group and with basic disease, especially a chronic respiratory disease, tended to have lower anti-SARS-CoV-2 antibody seroconversion rates.

Conclusion:

Antibodies that were elicited by these two inactivated COVID-19 vaccines appeared to wane following their peak after the second vaccine dose, but they persisted at detectable levels through 6 months after the second vaccine dose, and the effectiveness of these antibodies against the Delta variant of SARS-CoV-2 was lower than their effectiveness against wildtype SARS-CoV-2, which suggests that attention must be paid to the protective effectiveness, and its persistence, of COVID-19 vaccines on SARS-CoV-2 variants.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Aged / Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.939311

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Aged / Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.939311